全球生物模拟市场 - 按应用（药物开发、药物发现）、最终用户（製药公司、生物技术公司、学术机构、研究实验室）市场规模、份额和增长分析2023-2030行业预测

Global Biosimulation Market Size, Share, Growth Analysis, By Application(drug development, drug discovery), By End user(pharmaceutical and biotechnology companies, academic institutes and research laboratories) - Industry Forecast 2023-2030

出版日期: 2023年07月18日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021 年全球生物模拟市场价值将达到 24 亿美元，2022 年将达到 28.1 亿美元。预计该市场在预测期内（2023-2030年）将以16.9%的复合年增长率扩张，并于2030年扩大至97.8亿美元。

生物模拟是製药和生物技术行业使用的最先进技术。包括计算机建模和模拟，以了解生物过程、药物相互作用和疾病机制。这种创新方法使研究人员能够预测候选药物的结果并优化临床试验，从而降低成本并缩短上市时间。由于对个性化医疗的需求不断增加以及药物开发的复杂性不断增加，生物模拟市场正在显着增长。随着技术的进步，生物模拟有望在改变药物发现和药物开发过程中发挥关键作用。

主要驱动力之一是医疗保健基础设施的发展，通过提供昂贵的生物製剂的经济高效的替代品，增加了对生物仿製药的需求。此外，各种疾病患病率的上升以及对可获得和负担得起的治疗方法的需求进一步推动了对生物仿製药的需求。越来越多的专利到期药物和正在进行的临床试验中令人鼓舞的结果也有助于市场的扩张。

生物模拟技术在药物发现和开发中的使用缺乏标准化，并且采用不同的模型和技术来註册和处理生物事件。生物模拟固有的复杂性给研究人员在存储、操作和共享数据和模型方面带来了挑战。缺乏标准化方法阻碍了有效和可靠结果的产生，从而阻碍了生物模拟市场的增长。

本报告考察了全球生物模拟市场，并提供了市场概述、应用趋势、最终用户、地区以及进入市场的公司概况。

内容

执行摘要

母公司市场分析

市场规模

市场动态
驱动程序
机会
制约因素
任务

主要市场洞察

技术分析
价格分析
供应链分析
价值链分析
市场生态系统
知识产权分析
趋势分析
启动分析
原材料分析
创新矩阵
管道产品分析
宏观经济指标
热门投资分析
关键成功因素
争用程度

市场动态与展望

市场动态
驱动程序
机会
制约因素
任务
监管状况
波特分析

全球生物模拟市场，按应用划分

市场概况
药物开发
药物发现
其他

全球生物模拟市场，按最终用户划分

市场概况
製药公司、生物技术公司
学术机构、研究机构
合同研究组织
其他

全球生物模拟市场（按地区）

市场概况
北美
欧洲
亚太地区
拉丁美洲
中东和非洲

竞争格局

主要公司简介
Certara
Dassault Systemes SE
Simulations Plus Inc.
Schrodinger Inc.
Physiomics Plc
Advanced Chemistry Development Inc.
In silico biosciences Inc.
Genedata AG
Evidera Inc.
Leadscope Inc.
Insilico Biotechnology AG
Rhenovia Pharma SAS
Entelos Inc.
Biocomputing Platforms Ltd.
Rosa & Co. LLC
Genedata AG
OpenEye Scientific Software Inc.
Nexelis
Compugen Ltd.
Chemical Computing Group ULC

简介目录

Product Code: SQMIG35I2104

Market Insights

Bio simulation Market size was valued at USD 2.4 billion in 2021 and is poised to grow from USD 2.81 billion in 2022 to USD 9.78 billion by 2030, growing at a CAGR of 16.9% in the forecast period (2023-2030).

Biosimulation is a cutting-edge technology used in the pharmaceutical and biotechnology industries. It involves computer modeling and simulation to understand biological processes, drug interactions, and disease mechanisms. This innovative approach allows researchers to predict the outcomes of drug candidates and optimize clinical trials, reducing costs and time-to-market. The biosimulation market has witnessed substantial growth due to the increasing demand for personalized medicine and the rising complexity of drug development. As technology continues to advance, biosimulation is expected to play a pivotal role in revolutionizing drug discovery and development processes.

Top-down and bottom-up approaches were used to estimate and validate the size of bio simulation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biosimulation Market Segmental Analysis

The global biosimulation market is divided into three sections: offering type, application, and end user. The market is classified into two types of offerings: software and services. The software segment is divided into the following categories: PK/PD modelling and simulation, PBPK modelling and simulation, trial simulators, molecular modelling, and others. The Biosimulation Market is classified into three applications: drug discovery, drug development, and others. End users in the Biosimulation Market include contract research organisations, pharmaceutical and biotechnology companies, research institutes, regulatory institutes, and others. By region, the Biosimulation Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Driver

One of the primary factors is the development of healthcare infrastructure, which has led to an increased demand for biosimilars as they offer cost-effective alternatives to expensive biologics. Additionally, the prevalence of various diseases has risen, creating a greater need for accessible and affordable treatments, further boosting the demand for biosimilars. The growing number of off-patent drugs and encouraging results from ongoing clinical trials also contribute to the market's expansion.

Restraints

The utilization of biosimulation technologies in drug discovery and development lacks standardization, employing diverse models and techniques to register and process biological events. The inherent complexity of biosimulation poses challenges for researchers in terms of data and model storage, manipulation, and sharing. The absence of standardized practices hampers the generation of effective and dependable results, impeding the growth of the biosimulation market.

Market Trends

A significant factor contributing to market expansion is the increasing occurrence of drug relapse cases attributed to drug resistance in various diseases like cancer, tuberculosis, and bacterial infections. This trend is propelling the demand for innovative solutions and technologies, including biosimulation, to address the challenges posed by drug resistance and improve treatment outcomes for patients.